A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Completed · Phase 3 · NCT06192108
Conditions: Type 2 Diabetes
At a glance
- Research payments reported, 2025
- $1.5M
- U.S. investigators named
- 28
- Sites paid
- 21
- Planned or actual enrollment
- 962
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug), Dapagliflozin (drug)
- Dates
- Started 2024-01-10; completion 2025-09-26
- Results posted
- Yes
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
From ClinicalTrials.gov, last updated 2026-10-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.5M in research payments for this study in 2025 (48 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jitendra Sharma, M.B.B.S Neurology · Birmingham, AL
- Behnam Khaleghi, MD Rheumatology · Orange, CA
- Arash D. Matian, D.O. Family Medicine · Sherman Oaks, CA
- Steven H. Reynolds, D.O. Family Medicine · Long Beach, CA
- Apinya B. Vutikullird, D.O. Family Medicine · Cypress, CA
- Joseph Soufer, M.D. Internal Medicine · Waterbury, CT
- Shehzad M. Topiwala, MD Endocrinology & Diabetes · Stockbridge, GA
- Brian P. Beesley, M.D. Family Medicine · Rexburg, ID
- Yoko Momoyama, MD Internal Medicine · Lombard, IL
- Adil A. Fatakia, M.D. ENT (Otolaryngology) · Marrero, LA
- Siddharth Sehgal, M.D. Neurology · Burlington, MA
- Justen Rudolph, M.D. Internal Medicine · Billings, MT
- Trent L. Wei, MD Interventional Cardiology · Greensboro, NC
- Satkirin Khalsa Family Medicine · Albuquerque, NM
- Bliss J. Chang, MD Cardiology · Albany, NY
- Robert E. Dunn, MD Cardiac Electrophysiology · Cleveland, OH
- Medhat Farwati, MD Student in an Organized Health Care Education/Training Program · Cleveland, OH
- Devora Lichtman, MD Internal Medicine · Cleveland, OH
- Raunak M. Nair, MD Cardiology · Cleveland, OH
- Jeffrey E. Chasteen, DO Family Medicine · Tulsa, OK
- Lisa B. Connery, M.D. Family Medicine · Norman, OK
- Richard E. Mills, MD Internal Medicine · Mt Pleasant, SC
- Felix O. Berglund, MD Cardiology · Nashville, TN
- Zackary D. Goff, M.D. Cardiology · Nashville, TN
- John A. Kirby, M.D. Internal Medicine · Jefferson City, TN
- Julio Rosenstock, M.D. Endocrinology & Diabetes · Dallas, TX
- Damaris Vega, MD Endocrinology & Diabetes · Houston, TX
- Michelle D. Welch, MD Endocrinology & Diabetes · Shavano Park, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ark Clinical Research LLC $510,658
- Piedmont Medical Research Associates Inc $178,060
- Alliance Research Institute LLC $133,540
- Juno Research LLC $128,800
- Essential Medical Research LLC $124,214
- Collaborative Neuroscience Research LLC $86,299
- Velocity Clinical Research Inc $79,648
- Consano Clinical Research LLC $62,400
- Wolverine Clinical Trials LLC $53,643
- Cmr of Greater New Haven LLC $32,993
- Elite Clinical Trials Lllp $30,958
- Intermountain Health St Vincent Regional Hospital, MT $29,673
- Alliance for Multispecialty Research Lls $20,990
- Sitebridge Research Inc $20,843
- Albuquerque Clinical Trials Inc $19,676
- Tandem Clinical Research,llc $10,511
- Cleveland Clinic, OH $1,965
- Rheumatology Center of Houston $1,543
- Alliance Research Centers $636
- Mehrdad Kevin Ariani MD $525
- Intend Research LLC $405
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.